Jens G. Lohr
No Rating Available
(Learn About Our Rating System)

Jens G. Lohr, MD, PhD

Languages spoken: English

  • Dr. Lohr obtained his MD and PhD in Immunology at the Ruprecht-Karls University, Heidelberg, Germany. He conducted postdoctoral research in immunology and subsequently trained in Internal Medicine at UCSF. He completed a Hematology/Oncology fellowship at Dana–Farber Institute (Harvard Medical School), received further training in cancer genomics, and joined Dana Farber and the Broad Institute as an Assistant Professor of Medicine in 2016.

    His research interests are in multiple myeloma and cellular therapies, and he leads successful independent translational research programs in these areas. In addition to his responsibilities as CellReGen director, he has also been appointed Director of Immunotherapy research and is an Associate Professor in the Division of Hematology and Hematologic Malignancies..

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

  • Dr. Lohr obtained his MD and PhD in Immunology at the Ruprecht-Karls University, Heidelberg, Germany. He conducted postdoctoral research in immunology and subsequently trained in Internal Medicine at UCSF. He completed a Hematology/Oncology fellowship at Dana–Farber Institute (Harvard Medical School), received further training in cancer genomics, and joined Dana Farber and the Broad Institute as an Assistant Professor of Medicine in 2016.

    His research interests are in multiple myeloma and cellular therapies, and he leads successful independent translational research programs in these areas. In addition to his responsibilities as CellReGen director, he has also been appointed Director of Immunotherapy research and is an Associate Professor in the Division of Hematology and Hematologic Malignancies..

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Cancer Biology - Broad Institute of Massachusetts Institute of Technology & Harvard University Research Fellow
    Certification Translational Research - Dana-Farber Cancer Institute Certificate
    Fellowship Hematology/Oncology - Dana-Farber Cancer Institute, Partners CancerCare Clinical Fellow
    Fellowship Medicine - Harvard Medical School Clinical Fellow
    Certification Clinical Research - University of California, San Francisco Certificate
    Residency Internal Medicine - University of California, San Francisco Resident
    Other Training Immunology - University of California, San Francisco Postdoctoral Scholar
    Doctoral Training Immunology - Ruprecht-Karls-University/DKFZ Ph.D.
    Residency Internal Medicine: Hematology/Oncology - University Medical Center Freiburg Resident
    Professional Medical Medicine - Ruprecht-Karls-University of Heidelberg Faculty of Medicine M.D.

    Selected Publications

    Journal Article

    1. Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K (2023). Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv, 9(30), eadd6997. (Read full article)
    2. Im NG, Guillaumet-Adkins A, Wal M, Rogers AJ, Frede J, Havig CC, Yang J, Anand P, Stegmann SK, Waldschmidt JM, Sotudeh N, Niu L, Voisine J, Schweiger MR, Grassberger C, Lohr JG, Knoechel B (2021). Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. Cancer Immunol Res, 10(9), 1055-1068. (Read full article)
    3. Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, ODonnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG (2022). Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 36(4), 1078-1087. (Read full article)
    4. Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, Van Allen EM, Takeda DY, Loda M, Wu CL, Taplin ME, Garraway LA, Boehm JS, Huang FW (2022). Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate, 82(5), 584-597. (Read full article)
    5. Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, Potdar S, Nair MS, Vijaykumar T, Im NG, Guillaumet-Adkins A, Chopra N, Stuart H, Budano L, Sotudeh N, Guo G, Grassberger C, Yee AJ, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG (2021). Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res, 27(23), 6432-6444. (Read full article)
    6. Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, Yee AJ, Vijaykumar T, Waldschmidt JM, Potdar S, Kloeber JA, Kokkalis A, Dimitrova V, Mann M, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG (2021). Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol, 23(11), 1199-1211. (Read full article)
    7. Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad RI (2021). A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol, 119, 105366. (Read full article)
    8. Anand P, Guillaumet-Adkins A, Dimitrova V, Yun H, Drier Y, Sotudeh N, Rogers A, Ouseph MM, Nair M, Potdar S, Isenhart R, Kloeber JA, Vijaykumar T, Niu L, Vincent T, Guo G, Frede J, Harris MH, Place AE, Silverman LB, Teachey DT, Lane AA, DeAngelo DJ, Aster JC, Bernstein BE, Lohr JG, Knoechel B (2019). Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 137(18), 2463-2480. (Read full article)
    9. Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, ODonnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG (2018). Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia, 32(8), 1838-1841. (Read full article)
    10. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, OConnor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M (2017). Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun, 8(1), 1324. (Read full article)
    11. Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res, 23(15), 3980-3993. (Read full article)
    12. Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM (2016). The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep, 19(1), 218-224. (Read full article)
    13. Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, Gray D, Birrer N, Wong B, Ha G, Zhang CZ, Guo G, Meyerson M, Yee AJ, Boehm JS, Raje N, Golub TR (2015). Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med, 8(363), 363ra147. (Read full article)
    14. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC (2014). Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol, 32(5), 479-84. (Read full article)
    15. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein BE (2014). An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet, 46(4), 364-70. (Read full article)
    16. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Multiple Myeloma Research Consortium, Getz G, Golub TR (2013). Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell, 25(1), 91-101. (Read full article)
    17. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Corts ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457), 214-218. (Read full article)
    18. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ 3rd, Lohr JG, Harris CC, Ding L, Wilson RK, Wheeler DA, Gibbs RA, Kucherlapati R, Lee C, Kharchenko PV, Park PJ, Cancer Genome Atlas Research Network (2012). Landscape of somatic retrotransposition in human cancers. Science, 337(6097), 967-71. (Read full article)
    19. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareo C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernndez-Lemus E, Schwarz-Cruz y Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A, 109(10), 3879-84. (Read full article)
    20. Barron L, Knoechel B, Lohr J, Abbas AK (2008). Cutting edge: contributions of apoptosis and anergy to systemic T cell tolerance. J Immunol, 180(5), 2762-6. (Read full article)
    21. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK (2006). Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med, 203(13), 2785-91. (Read full article)
    22. Knoechel B, Lohr J, Zhu S, Wong L, Hu D, Ausubel L, Abbas AK (2006). Functional and molecular comparison of anergic and regulatory T lymphocytes. J Immunol, 176(11), 6473-83. (Read full article)
    23. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK (2005). Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med, 202(10), 1375-86. (Read full article)
    24. Knoechel B, Lohr J, Kahn E, Abbas AK (2005). The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol, 175(1), 21-6. (Read full article)
    25. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V (2004). T cell tolerance and autoimmunity. Autoimmun Rev, 3(7-8), 471-5. (Read full article)
    26. Lohr J, Knoechel B, Kahn EC, Abbas AK (2004). Role of B7 in T cell tolerance. J Immunol, 173(8), 5028-35. (Read full article)
    27. Lohr J, Mielke S, Lbbert M, Behringer D (2003). Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. In Vivo, 17(5), 505-7. (Read full article)
    28. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK (2003). The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol, 4(7), 664-9. (Read full article)
    29. Zeller Y, Lohr J, Sammar M, Butcher EC, Altevogt P (1998). Asp-698 and Asp-811 of the integrin alpha4-subunit are critical for the formation of a functional heterodimer. J Biol Chem, 273(12), 6786-95. (Read full article)
    30. Altevogt P, Hubbe M, Ruppert M, Lohr J, von Hoegen P, Sammar M, Andrew DP, McEvoy L, Humphries MJ, Butcher EC (1995). The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. J Exp Med, 182(2), 345-55. (Read full article)

    Review

    1. Waldschmidt JM, Vijaykumar T, Knoechel B, Lohr JG (2020). Tracking myeloma tumor DNA in peripheral blood. [Review]. Best Pract Res Clin Haematol, 33(1), 101146. (Read full article)
    2. Holstein SA, Avet-Loiseau H, Hahn T, Ho CM, Lohr JG, Munshi NC, Paiva B, Pasquini MC, Tario JD Jr, Usmani SZ, Wallace PK, Weisel K, McCarthy PL (2017). BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. [Review]. Biol Blood Marrow Transplant, 24(4), 641-648. (Read full article)
    3. Waldschmidt JM, Anand P, Knoechel B, Lohr JG (2018). Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. [Review]. Semin Hematol, 55(1), 33-37. (Read full article)
    4. Knoechel B, Lohr JG (2013). Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. [Review]. J Autoimmun, 45, 15-23. (Read full article)
    5. Lohr J, Knoechel B, Caretto D, Abbas AK (2009). Balance of Th1 and Th17 effector and peripheral regulatory T cells. [Review]. Microbes Infect, 11(5), 589-93. (Read full article)
    6. Abbas AK, Lohr J, Knoechel B (2007). Balancing autoaggressive and protective T cell responses. [Review]. J Autoimmun, 28(2-3), 59-61. (Read full article)
    7. Lohr J, Knoechel B, Abbas AK (2006). Regulatory T cells in the periphery. [Review]. Immunol Rev, 212, 149-62. (Read full article)
    8. Lohr J, Knoechel B, Nagabhushanam V, Abbas AK (2005). T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. [Review]. Immunol Rev, 204, 116-27. (Read full article)
    9. Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F (2002). [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. [Review]. Strahlenther Onkol, 180(6), 331-9. (Read full article)
    10. Herskind C, Fleckenstein K, Lohr J, Li CY, Wenz F, Lohr F (2002). [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. [Review]. Strahlenther Onkol, 180(4), 187-93. (Read full article)